New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
07:03 EDTOMEROmeros announces positive OMS302 safety data in Phase 3 clinical trial
Omeros announced the successful completion of the 90-day safety database lock in the second of the company's two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302 is Omeros' proprietary PharmacoSurgery product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. Safety data were collected through postoperative day 90. In this Phase 3 clinical trial, OMS302 was well tolerated. No safety concerns have been identified in the OMS302 clinical development program.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:16 EDTOMERAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
October 7, 2014
07:06 EDTOMEROmeros, Hospira enter into commercial suply agreement for Omidria
Omeros Corporation (OMER) said in a filing that on October 3, it, Hospira S.p.A. and Hospira Worldwide, Inc. (HSP) entered into a Commercial Supply Agreement, pursuant to which Hospira will act as a non-exclusive supplier of Omerosí product Omidria for commercial sale in the United States and the European Union. Pursuant to the Supply Agreement, Hospira has agreed to manufacture and supply, and Omeros has agreed to purchase, a minimum percentage of Omerosí requirements of Omidria for commercial sales and clinical supplies for the development of additional therapeutic indications in the United States. In addition, upon receipt of marketing approval in the EU, Hospira has agreed to manufacture and supply a portion of Omerosí requirements of Omidria in the EU in an amount to be mutually agreed by the parties within four months of marketing approval in Europe, with there being no minimum purchase and supply requirement in the EU if the parties do not reach agreement during such time period and the agreement is not amended thereafter. The Supply Agreement obligates Omeros to provide to Hospira a rolling, non-binding long-term forecast of Omerosí estimated required quantities of Omidria. The Supply Agreement has an initial term of five years from the date of first commercial sale of Omidria in any country in the Territory. Upon termination of the Supply Agreement, except in the case of termination for an uncured breach by Hospira, Omeros will be required to purchase all of Hospiraís inventory of Omidria and, if applicable, work in progress and reimburse Hospira for all supplies purchased or ordered based on firm purchase orders or Omerosí estimates of its requirements of Omidria.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use